Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28570981 | 0.89 | KMT2A (0.55) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL28570980 | 0.89 | KMT2A (0.55) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL17845364 | 0.88 | ALDH1A1 (0.49) | KMT2ARAB9AMEN1MAPTHTT | |
| SCHEMBL19232114 | 0.84 | ALDH1A1 (0.64) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL8895665 | 0.84 | KMT2A (0.51) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL19707984 | 0.84 | KMT2A (0.66) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL12780368 | 0.83 | RECQL (0.61) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL14254797 | 0.83 | ALDH1A1 (0.55) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL19987418 | 0.83 | ALDH1A1 (0.56) | KMT2ASMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL7230992 | 0.81 | KDM4E (0.51) | KMT2ANPC1RAB9AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-10167254-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-15 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167254-B2 | IDO inhibitors | IDO1, IDO2, INMT | KMT2A 461/4885SMN1; SMN2 4280/4885NPC1 2825/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KMT2A 461/4885SMN1; SMN2 4280/4885NPC1 2825/4885 |
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KMT2A 400/4885SMN1; SMN2 4521/4885NPC1 2350/4885 |
| US-20180072660-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KMT2A 400/4885SMN1; SMN2 4521/4885NPC1 2350/4885 |
| US-10399933-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | KMT2A 400/4885SMN1; SMN2 4521/4885NPC1 2350/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KMT2A 461/4885SMN1; SMN2 4280/4885NPC1 2825/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | KMT2A 400/4885SMN1; SMN2 4521/4885NPC1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.